Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 224,684,219 papers from all fields of science
Search
Sign In
Create Free Account
MK-0366
Known as:
MK 366
, MK 0366
, MK366
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
1 relation
Broader (1)
Norfloxacin
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
1986
1986
The comparative in-vitro activity of norfloxacin, ciprofloxacin, enoxacin and nalidixic acid against 423 strains of gram-negative rods and staphylococci isolated from infected hospitalised patients.
M. Guimarães
,
P. Noone
Journal of Antimicrobial Chemotherapy
1986
Corpus ID: 27087269
The in-vitro activities of four quinolone carboxylic acids against 423 clinical isolates of Gram-negative rods and staphylococci…
Expand
1983
1983
Tentative interpretive standards for disk diffusion susceptibility testing with norfloxacin (MK-0366, AM-715)
H. H. Gadebusch
Antimicrobial Agents and Chemotherapy
1983
Corpus ID: 42889249
Norfloxacin is a new orally absorbed quinoline derivative structurally related to nalidixic acid but showing an expanded…
Expand
1983
1983
Norfloxacin (MK-0366) treatment of urinary tract infections in hospitalized patients.
G. Panichi
,
A. Pantosti
,
G. Testore
Journal of Antimicrobial Chemotherapy
1983
Corpus ID: 30413127
Norfloxacin (MK-0366) is a new antibacterial agent, closely related to nalidixic acid, with broad spectrum activity against Gram…
Expand
1983
1983
The comparative activity of norfloxacin with other antimicrobial agents against Gram-positive and Gram-negative bacteria.
M. Corrado
,
C. Cherubin
,
M. Shulman
Journal of Antimicrobial Chemotherapy
1983
Corpus ID: 24679052
Norfloxacin (MK0366) displayed appreciable activity against the great majority of Gram-negative and Gram-positive bacteria. The…
Expand
1983
1983
Comparative activities of norfloxacin and fifteen other antipseudomonal agents against gentamicin-susceptible and -resistant Pseudomonas aeruginosa strains
K. Forward
,
G. Harding
,
G. J. Gray
,
B. Urias
,
A. Ronald
Antimicrobial Agents and Chemotherapy
1983
Corpus ID: 46601650
We compared the activity of norfloxacin (MK-0366), a new orally absorbable derivative of naladixic acid, with those of other…
Expand
1983
1983
Comparative in vitro activity of norfloxacin against urinary tract pathogens
D. Haase
,
B. Urias
,
G. Harding
,
A. Ronald
European Journal of Clinical Microbiology
1983
Corpus ID: 32484537
The in vitro activity of norfloxacin (MK366) against 477 aerobic gram-negative and gram-positive clinical isolates was compared…
Expand
1983
1983
Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
R. Jones
,
A. Barry
Diagnostic microbiology and infectious disease
1983
Corpus ID: 30310049
1983
1983
In vitro activity of norfloxacin in urine compared to that of cinnoxacin, nalidixic acid and pipemidic acid
P. Shah
,
M. Ottrad
,
W. Stille
European Journal of Clinical Microbiology
1983
Corpus ID: 39863788
1. Ito, A., Hirai, K., Inoue, M., Koga, H., Suzue, S., Irikura, T., Mitsuhashi, S.: In vitro antibacterial activity of AM-715, a…
Expand
1983
1983
In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
A. Vuye
Arzneimittel-Forschung
1983
Corpus ID: 39984249
1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-3-quinolinecarbo xylic acid (Norfloxacin, MK-0366), a new nalidixic acid…
Expand
Highly Cited
1982
Highly Cited
1982
Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates
M. Y. Khan
,
R. Gruninger
,
S. Nelson
,
R. Klicker
Antimicrobial Agents and Chemotherapy
1982
Corpus ID: 24569880
The in vitro activity of a new oral antimicrobial agent, norfloxacin (MK-0366), was compared with those of nalidixic acid…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE